Biologics Overshadow Small Molecules In US FDA’s 2023 Novel Approvals
Gene therapies, bispecific antibodies and vaccines stand out among 2023’s 34 novel biologics and the US FDA’s 38 new molecular entities include fewer breakthroughs.
Gene therapies, bispecific antibodies and vaccines stand out among 2023’s 34 novel biologics and the US FDA’s 38 new molecular entities include fewer breakthroughs.